Pathologists and the third wave of medical genomics

Personalized Medicine

Volumn 9, Issue 3, 2012, Pages 241-242

  Boguski, Mark S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

diagnostic services; genetic polymorphisms; genomics; healthcare reform; laboratory accreditation; laboratory medicine; multifactorial diseases; personalized medicine; pharmaceutical industry; presymptomatic genotyping; validated drug targets

Indexed keywords

ACCREDITATION; CERTIFICATION; CLINICAL DECISION MAKING; COOPERATION; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; EDITORIAL; FUNCTIONAL GENOMICS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME; GENOMICS; GENOTYPE; HEALTH CARE COST; HEALTH PROMOTION; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMISM; PATHOLOGIST; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; STRUCTURAL GENOMICS;

EID: 84860723532     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.27     Document Type: Editorial

References (18)

1. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14(11), 1516-1518 (1996).
2. Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Dis. 1(9), 727-730 (2002). (Pubitemid 37361545)
3. Bassett DE Jr, Boguski MS, Spencer F et al. Genome cross-referencing and XREFdb: implications for the identification and analysis of genes mutated in human disease. Nat. Genet. 15(4), 339-344 (1997). (Pubitemid 27147100)
4. Hieter P, Boguski M. Functional genomics: it's all how you read it. Science 278(5338), 601-602 (1997). (Pubitemid 27464949)
5. Shapiro L, Lima CD. The argonne structural genomics workshop: lamaze class for the birth of a new science. Structure 6(3), 265-267 (1998).
6. Burton PR, Clayton DG, Cardon LR, et al.; Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 477(7145), 661-678 (2007). (Pubitemid 46889737)
7. Davies K. The $1,000 genome: the revolution in DNA sequencing and the new era of personalized medicine. Free Press, NY, USA (2010).
8. Davies K. Keeping score of your sequence. Bio-IT World, 12 November (2008).
9. Haspel RL, Arnaout R, Briere L et al. A Curriculum in genomics and personalized medicine for pathology residents. Am. J. Clin. Path. 133(Online Suppl.), 1-3 (2010).
10. Bloss CS, Madlensky L, Schork NJ, Topol EJ. Genomic information as a behavioral health intervention: can it work? Per. Med. 8(6), 659-667 (2011).
11. Boguski MS, Arnaout R, Hill C. Customized care 2020: how medical sequencing and network biology will enable personalized medicine. F1000 Biol. Rep. 1, 73 (2009).
12. Christensen CM, Grossman JH, Hwang J. The innovator's prescription: a disruptive solution for health care. McGraw-Hill, NY, USA (2009).
13. Mardis ER. A decade's perspective on DNA sequencing technology. Nature 470(7333), 198-203 (2011).
14. Kuehn BG. NIH shifts focus from sequencing genes to fostering clinical applications. JAMA 307(2), 132 (2012).
15. Haspel RL, Arnaout R, Briere L et al. A call to action: training pathology residents in genomics and personalized medicine. Am. J. Clin. Pathol. 133(6), 832-834 (2010).
16. Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the banbury conference center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am. J. Clin. Pathol. 135(5), 668-672 (2011).
17. Centers for Medicare & Medicaid Services; US Department of Health and Human Services. Medicare, Medicaid and CLIA programs; continuance of the approval of the College of American Pathologists as a CLIA accreditation organization. Federal Register 66(177), 47493-47497 (2001).
18. Rabinovitch A. The college of American pathologists laboratory accreditation program. Accreditation and quality assurance. J. Qual. Comparability Reliability Chem. Measurement 7(11), 473-476 (2002) (Pubitemid 36165310)